Breaking News

Tweet TWEET

Pushing Pipelines Forward for Long-Term Success - Research Report on Vertex, Santarus, Arena Pharmaceuticals, Seattle Genetics

 Pushing Pipelines Forward for Long-Term Success - Research Report on Vertex,
  Santarus, Arena Pharmaceuticals, Seattle Genetics and Nektar Therapeutics

PR Newswire

NEW YORK, March 8, 2013

NEW YORK, March 8, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Vertex
Pharmaceuticals Incorporated (NASDAQ: VRTX), Santarus, Inc. (NASDAQ: SNTS),
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Seattle Genetics, Inc. (NASDAQ:
SGEN) and Nektar Therapeutics (NASDAQ: NKTR). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Vertex Pharmaceuticals Incorporated Research Report

Vertex Pharmaceuticals recently revealed data from its Phase 2 influenza
challenge study, saying that its investigational medicine VX-787 was able to
reduce viral shedding by 94 percent versus placebo. There was also a
statistically significant reduction in the severity and duration of
influenza-like symptoms for patients that were given the highest dosage. These
successful results bring Vertex closer to completing the development of a drug
that directly inhibits replication of influenza A, including H1 and H5
influenza strains. Aside from this, Vertex is also developing treatments for
cystic fibrosis, hepatitis c and autoimmune diseases. With a clear business
strategy and productive R&D programs, Vertex is on its way to significant
growth. The Full Research Report on Vertex Pharmaceuticals Incorporated -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/59ce_VRTX]

--

Santarus, Inc. Research Report

Santarus is starting the year strong after the FDA approved UCERIS, its
treatment for patients with active, mild to moderate ulcerative colitis. It
also re-launched its ZEGERID drug weeks ago. Last year, the company was able
to advance its pipeline, reporting positive Phase III results for a couple of
its drugs including RUCONEST, its treatment for hereditary angioedema. It also
reported record annual record revenue of $218 million. With commercial success
for its products as well as a string of approvals from the FDA, Santarus is
poised for another year of excellent results. The Full Research Report on
Santarus, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/7f82_SNTS]

--

Arena Pharmaceuticals, Inc. Research Report

Arena Pharmaceuticals recently reported its fourth quarter and full year 2012
results, with 27.6 million for the full year compared to $12.7 million in
2011. Furthermore, the FDA recently approved the company's first drug, BELVIQ,
a weight loss and weight management drug for obese and overweight patients.
BELVIQ will be available by prescription in the United States and it has also
been filed for approval to the Korea Food and Drug Administration. Aside from
this, Arena Pharmaceuticals has a treatment for pulmonary arterial
hypertension in development. By expanding to new markets and by advancing its
pipeline, Arena Pharmaceuticals is positioning itself for long-term growth.
The Full Research Report on Arena Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/3996_ARNA]

--

Seattle Genetics, Inc. Research Report

Seattle Genetics is currently in the process of bringing its lymphatic disease
drug ADCETRIS to commercial success. Last year, the company reported ADCETRIS
net product sales of $35.4 million in the fourth quarter and $138.2 million
for the entire year. Going forward, the company has 20 ADCETRIS clinical
trials to broadly explore its therapeutic potential. The company also expects
to submit an investigational new drug application to the FDA for a number of
drugs, including one for myeloid leukemia and breast cancer. With a strong
financial position and cash flow from product sales, the company is set to
fulfill these goals. The Full Research Report on Seattle Genetics, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/e97f_SGEN]

--

Nektar Therapeutics Research Report

Nektar Therapeutics is confident about the coming year, with five late-stage
programs tackling multiple therapeutic areas. Furthermore, Nektar
Therapeutics' partner in developing naloxegol, AstraZeneca, is preparing to
submit registrations filings in the US and EU in the third quarter this year.
It also has programs for pneumonia and a potential breakthrough for the
treatment of chronic pain. Recognizing Nektar Therapeutics' potential,
Deutsche Bank raised its price target for shares of Nektar Therapeutics to
$13, and reiterated its Buy rating on the stock. Analysts at Deutsche Bank
note the company's cash balance of $302 million, which may be "more than
enough to allow the company to reach its key milestones." The Full Research
Report on Nektar Therapeutics - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/62a3_NKTR]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance
 
Press spacebar to pause and continue. Press esc to stop.